Investors

Mission

Bring Health
Closer to You

Founded in 2014, Prenetics is a major global diagnostics and genetic testing company with the mission to bring health closer to millions of people globally and decentralize healthcare by making the three pillars — Prevention, Diagnostics and Personalized Care — comprehensive and accessible to anyone, at anytime and anywhere.

Prenetics is led by visionary entrepreneur, Danny Yeung, with operations across 9 locations, including United Kingdom, Hong Kong, India, South Africa, and Southeast Asia.

Prenetics develops consumer genetic testing and early colorectal cancer screening; provides COVID-19 testing, rapid point of care and at-home diagnostic testing and medical genetic testing.

Investors
Presentation

Download the latest Investor
Presentation below

Press
Release

[September 16, 2021] - Prenetics, a Global Leader in Genomic and Diagnostic Testing, to Become Publicly-Traded on the Nasdaq via Merger with Adrian Cheng’s Artisan Acquisition Corp.

View Press Release

Analyst
Presentation

Download the latest Analyst
Presentation below

Press
Release

[September 16, 2021] - Prenetics, a Global Leader in Genomic and Diagnostic Testing, to Become Publicly-Traded on the Nasdaq via Merger with Adrian Cheng’s Artisan Acquisition Corp.

View Press Release
Press Release
May 12, 2022

Prenetics and Artisan Acquisition Corp. Announce Shareholder Approval of Business Combination, To Begin Trading on Nasdaq on May 18 Under the Ticker “PRE”

May 4, 2022

Prenetics Reports Record First Quarter 2022 Preliminary Financial Results. Nasdaq Listing in Partnership with Artisan Acquisition Corp. Expected on May 18, 2022

Get in touch

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.